{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T19:15:56Z","timestamp":1713813356727},"reference-count":114,"publisher":"Wiley","issue":"s5","license":[{"start":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T00:00:00Z","timestamp":1402617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The 4th Haemophilia Global Summit was held in Potsdam, Germany, in September 2013 and brought together an international faculty of haemophilia experts and delegates from multidisciplinary backgrounds. The programme was designed by an independent Scientific Steering Committee of haemophilia experts and explored global perspectives in haemophilia care, discussing practical approaches to the optimal management of haemophilia now and in the future. The topics outlined in this supplement were selected by the Scientific Steering Committee for their relevance and potential to influence haemophilia care globally. In this supplement from the meeting, Jan Astermark reviews current understanding of risk factors for the development of inhibitory antibodies and discusses whether this risk can be modulated and minimized. Factors key to the improvement of joint health in people with haemophilia are explored, with Carlo Martinoli and V\u00edctor Jim\u00e9nez\u2010Yuste discussing the utility of ultrasound for the early detection of haemophilic arthropathy. Other aspects of care necessary for the prevention and management of joint disease in people with haemophilia are outlined by Thomas Hilberg and S\u00e9bastian Lobet, who highlight the therapeutic benefits of physiotherapy and sports therapy. Riitta Lassila and Carlo\u2010Federico Perno describe current knowledge surrounding the risk of transmission of infectious agents via clotting factor concentrates. Finally, different types of extended half\u2010life technology are evaluated by Mike Laffan, with a focus on the practicalities and challenges associated with these products.<\/jats:p>","DOI":"10.1111\/hae.12468","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T10:39:19Z","timestamp":1402655959000},"page":"1-20","source":"Crossref","is-referenced-by-count":7,"title":["Managing Haemophilia for Life: 4th Haemophilia Global Summit"],"prefix":"10.1111","volume":"20","author":[{"given":"J.","family":"Astermark","sequence":"first","affiliation":[{"name":"Department of Hematology and Vascular Disorders, Sk\u00e5ne University Hospital Malm\u00f6\/Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Dolan","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospital Queen's Medical Centre Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hilberg","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine University Wuppertal Wuppertal Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Jim\u00e9nez\u2010Yuste","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Laffan","sequence":"additional","affiliation":[{"name":"Imperial College London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Lassila","sequence":"additional","affiliation":[{"name":"Helsinki University Central Hospital Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lobet","sequence":"additional","affiliation":[{"name":"Division of Physical Medicine and Rehabilitation &amp; Haemostasis and Thrombosis Unit Division of Haematology Cliniques Universitaires Saint\u2010Luc Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Martinoli","sequence":"additional","affiliation":[{"name":"University of Genoa Genoa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.\u2010F.","family":"Perno","sequence":"additional","affiliation":[{"name":"University of Rome \u2018Tor Vergata\u2019 Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,13]]},"reference":[{"key":"e_1_2_42_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61139-2"},{"key":"e_1_2_42_3_1","unstructured":"Steen\u2010CarlssonK.Personal communication[unpublished data]."},{"key":"e_1_2_42_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03538.x"},{"key":"e_1_2_42_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.01009.x"},{"key":"e_1_2_42_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01261.x"},{"key":"e_1_2_42_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03417.x"},{"key":"e_1_2_42_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-336198"},{"key":"e_1_2_42_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2001.00134.x"},{"key":"e_1_2_42_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02420.x"},{"key":"e_1_2_42_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00510.x"},{"key":"e_1_2_42_12_1","first-page":"924","article-title":"The Malm\u00f6 International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A","volume":"90","author":"Astermark J","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_42_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379453"},{"key":"e_1_2_42_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12004"},{"key":"e_1_2_42_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3270"},{"key":"e_1_2_42_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01375.x"},{"key":"e_1_2_42_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3918"},{"key":"e_1_2_42_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024711"},{"key":"e_1_2_42_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02290.x"},{"key":"e_1_2_42_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345203"},{"key":"e_1_2_42_21_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5916.92623"},{"key":"e_1_2_42_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03636.x"},{"key":"e_1_2_42_23_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-06-0425"},{"key":"e_1_2_42_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12168"},{"key":"e_1_2_42_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02473.x"},{"key":"e_1_2_42_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-313X.2009.00893.x"},{"key":"e_1_2_42_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22746"},{"key":"e_1_2_42_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-434803"},{"key":"e_1_2_42_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00287"},{"key":"e_1_2_42_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03823.x"},{"key":"e_1_2_42_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208024"},{"key":"e_1_2_42_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302183280701"},{"key":"e_1_2_42_33_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.06019"},{"key":"e_1_2_42_34_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH03-10-0643"},{"key":"e_1_2_42_35_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1356715"},{"key":"e_1_2_42_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02231.x"},{"key":"e_1_2_42_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056291"},{"key":"e_1_2_42_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01088.x"},{"key":"e_1_2_42_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02122.x"},{"key":"e_1_2_42_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02659.x"},{"key":"e_1_2_42_41_1","doi-asserted-by":"crossref","unstructured":"AuerswaldG KurnikK BlatnyJet\u00a0al.The EPIC Study:\u00a0A Clinical Trial To Assess Whether Early Low Dose Prophylaxis In The Absence Of Immunological Danger Signals Reduces Inhibitor Incidence In Previously Untreated Patients (PUPs) With Hemophilia A. Abstract No. 576. American Society of Hematology Annual Meeting New Orleans 2013.","DOI":"10.1182\/blood.V122.21.576.576"},{"key":"e_1_2_42_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457036"},{"key":"e_1_2_42_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01414.x"},{"key":"e_1_2_42_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03160.x"},{"key":"e_1_2_42_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02380.x"},{"key":"e_1_2_42_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02680.x"},{"key":"e_1_2_42_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02672.x"},{"key":"e_1_2_42_48_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-11-0874"},{"key":"e_1_2_42_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07386.x"},{"key":"e_1_2_42_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01534.x"},{"key":"e_1_2_42_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119979401.ch30"},{"key":"e_1_2_42_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02835.x"},{"key":"e_1_2_42_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01080.x"},{"key":"e_1_2_42_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/00016470510030382"},{"key":"e_1_2_42_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0474-7"},{"key":"e_1_2_42_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02711.x"},{"key":"e_1_2_42_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01748.x"},{"key":"e_1_2_42_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01266.x"},{"key":"e_1_2_42_59_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00563.x"},{"key":"e_1_2_42_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12034"},{"key":"e_1_2_42_61_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00679.x"},{"key":"e_1_2_42_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12031"},{"key":"e_1_2_42_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-4388(94)90137-6"},{"key":"e_1_2_42_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02466.x"},{"key":"e_1_2_42_65_1","unstructured":"Haemophilia and Exercise Project. Available atwww.haemophilia-exercise.de. Accessed May 2014."},{"key":"e_1_2_42_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.04.030"},{"key":"e_1_2_42_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61199-4"},{"key":"e_1_2_42_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750\u20101172\u20107\u201024"},{"key":"e_1_2_42_69_1","volume-title":"in Textbook of Haemophilia","author":"Makris M","year":"2010"},{"key":"e_1_2_42_70_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00734.x"},{"key":"e_1_2_42_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb07444.x"},{"key":"e_1_2_42_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.1.254.254"},{"key":"e_1_2_42_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200402200-00020"},{"key":"e_1_2_42_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)05413-5"},{"key":"e_1_2_42_75_1","unstructured":"National Hemophilia Foundation.HIV\/AIDS. Available atwww.hemophilia.org\/NHFWeb\/MainPgs\/MainNHF.aspx?menuid=43&contentid=39. Accessed May 2014."},{"key":"e_1_2_42_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12423"},{"key":"e_1_2_42_77_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084145"},{"key":"e_1_2_42_78_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1354420"},{"key":"e_1_2_42_79_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2001.0899"},{"key":"e_1_2_42_80_1","first-page":"167","article-title":"Emerging and re\u2010emerging viruses in the era of globalisation","volume":"7","author":"Zappa A","year":"2009","journal-title":"Blood Transfus"},{"key":"e_1_2_42_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03907.x"},{"key":"e_1_2_42_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02181.x"},{"key":"e_1_2_42_83_1","unstructured":"P Archer N Jones J Willets"},{"key":"e_1_2_42_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01341.x"},{"key":"e_1_2_42_85_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00701.x"},{"key":"e_1_2_42_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03420.x"},{"key":"e_1_2_42_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12060"},{"key":"e_1_2_42_88_1","unstructured":"MannucciPM.WFH 2004. Available atwww1.wfh.org\/publication\/files\/pdf-1267.pdf\u200e. Accessed May 2014."},{"key":"e_1_2_42_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7019.1549"},{"key":"e_1_2_42_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68036-7"},{"key":"e_1_2_42_91_1","unstructured":"EMA 2011 position statement:www.ema.europa.eu\/docs\/en_GB\/document_library\/Position_statement\/2011\/06\/WC500108071.pdf. Accessed November 2013."},{"key":"e_1_2_42_92_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-946908"},{"key":"e_1_2_42_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0435-x"},{"key":"e_1_2_42_94_1","first-page":"292","article-title":"Plasma\u2010derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better","volume":"8","author":"Franchini M","year":"2010","journal-title":"Blood Transfus"},{"key":"e_1_2_42_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01695.x"},{"issue":"2","key":"e_1_2_42_96_1","first-page":"4","article-title":"The manufacturing process for recombinant factor IX","volume":"35","author":"Harrison S","year":"1998","journal-title":"Semin Hematol"},{"key":"e_1_2_42_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02160.x"},{"key":"e_1_2_42_98_1","first-page":"366","article-title":"Factor VIII safety: plasma\u2010derived versus recombinant products","volume":"9","author":"Gringeri A","year":"2011","journal-title":"Blood Transfus"},{"key":"e_1_2_42_99_1","unstructured":"World Federation of Hemophilia Annual Global Survey2011. Available atwww1.wfh.org\/publications\/files\/pdf-1488.pdf. Accessed May 2014."},{"key":"e_1_2_42_100_1","first-page":"362","article-title":"A retrospective study of the practice of \u201clook\u2010back\u201d procedures, on the incidence of HIV\u20101\/2\u2010positive blood donors and the risk of transfusion\u2010associated HIV infection in public\u2010community blood banks in Germany","volume":"21","author":"Zeiler T","year":"1994","journal-title":"Infusionsther Transfusionsmed"},{"key":"e_1_2_42_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(10)70150-X"},{"key":"e_1_2_42_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.5.1809.1809"},{"key":"e_1_2_42_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02572.x"},{"key":"e_1_2_42_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2081"},{"key":"e_1_2_42_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-360594"},{"key":"e_1_2_42_106_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613759"},{"key":"e_1_2_42_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-254755"},{"key":"e_1_2_42_108_1","unstructured":"RadkeS WalschR KerschgensBet\u00a0al.Clinical Development Program for BAY 94\u20109027 a Long\u2010Acting PEGylated B\u2010Domain\u2212Deleted Recombinant Factor VIII for Patients With Hemophilia A. Presented at: Optimal use of clotting factors and immunoglobulins;2013; Wildbad Kreuth Germany."},{"key":"e_1_2_42_109_1","unstructured":"Baxter Bioscience.BAX 855 a PEGylated rFVIII product with prolonged half\u2010life. Presented at: Optimal use of clotting factors and immunoglobulins;2013; Wildbad Kreuth Germany."},{"key":"e_1_2_42_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-407494"},{"key":"e_1_2_42_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12161"},{"key":"e_1_2_42_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-382846"},{"key":"e_1_2_42_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-367003"},{"key":"e_1_2_42_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02931.x"},{"key":"e_1_2_42_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2001.00471.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12468","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T23:52:04Z","timestamp":1694649124000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,13]]},"references-count":114,"journal-issue":{"issue":"s5","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/hae.12468"],"URL":"https:\/\/doi.org\/10.1111\/hae.12468","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,13]]}}}